BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16149615)

  • 1. [Gamma-seminoprotein (gamma-Sm)].
    Miyahara S
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():698-701. PubMed ID: 16149615
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of 3 assay kits of prostate specific antigen in serum of prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Dec; 34(12):2143-8. PubMed ID: 2467543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of prostate specific antigen and gamma-seminoprotein ratio for diagnosing prostate cancer].
    Akino H; Suzuki Y; Okada K
    Nihon Rinsho; 1998 Aug; 56(8):2003-5. PubMed ID: 9750496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostatic acid phosphatase (PAP)].
    Kuriyama M
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():702-4. PubMed ID: 16149616
    [No Abstract]   [Full Text] [Related]  

  • 5. [Specific quantification of gamma-seminoprotein-alpha 1 antichymotrypsin complex in serum by monoclonal antibody-based enzyme immunoassay].
    Chichibu K; Kuroe K; Hashimoto C; Goto S
    Rinsho Byori; 1995 Nov; 43(11):1153-8. PubMed ID: 8551680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of serum prostatic specific antigen in prostatic cancer: simultaneous assays of prostatic specific antigen, gamma-seminoprotein and prostatic acid phosphatase in 113 newly diagnosed patients with prostatic cancer].
    Arai Y; Yoshki T; Okada K; Yoshida O; Yamamoto N; Sakatoku J; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 1989 Sep; 35(9):1519-28. PubMed ID: 2479237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [gamma-Seminoprotein (gamma-Sm)].
    Miyahara S
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():743-6. PubMed ID: 20963907
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer].
    Kamachi S; Sakurabayashi I; Kawai T
    Rinsho Byori; 1984 Jul; 32(7):781-5. PubMed ID: 6389940
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of gamma-seminoprotein (gamma-SM) and prostatic acid phosphatase (PAP) as tumor markers of prostatic cancer].
    Watanabe M; Kitamura Y; Komatsubara S; Sakata Y
    Hinyokika Kiyo; 1988 Dec; 34(12):2135-41. PubMed ID: 2467542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].
    Akimoto S; Akakura K; Shimazaki J
    Hinyokika Kiyo; 1988 Aug; 34(8):1389-96. PubMed ID: 2461644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of gamma-seminoprotein as a serum marker of prostate carcinoma].
    Sugimura Y; Sakurai M; Hioki T; Hayashi N; Yamakawa K; Tajima K; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1988 Dec; 34(12):2129-34. PubMed ID: 2467541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
    Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
    Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of tumor markers in prostatic carcinoma--an investigation on the simultaneous measurement of prostatic acid phosphatase (PAP), prostatic antigen (PA) and gamma-seminoprotein (gamma-Sm)].
    Tsukamoto T; Kumamoto Y; Yamazaki K; Umehara T; Miyao N; Ohmura K; Iwazawa M
    Hinyokika Kiyo; 1988 Jun; 34(6):987-95. PubMed ID: 2464917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The present status and future directions for standardization of PSA assays in PSA gray zone].
    Kurokawa K; Yamanaka H; Ishibashi M; Kano S; Arai Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():117-22. PubMed ID: 12599556
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical studies of gamma-seminoprotein in prostatic disease. I. Clinical evaluation of serum gamma-seminoprotein].
    Hasegawa S; Nakashima J; Nakashima Y; Nakamura S; Kimura S
    Hinyokika Kiyo; 1987 Dec; 33(12):2055-8. PubMed ID: 3329453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Present status of serum total PSA assay and factors responsible for the inter-kit deviations].
    Kano S
    Nihon Rinsho; 2000 Jul; 58 Suppl():112-7. PubMed ID: 11022696
    [No Abstract]   [Full Text] [Related]  

  • 20. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.